Barclays Starts Zimmer Biomet (ZBH) at Underweight

Barclays analyst Matt Miksic initiates coverage on Zimmer Biomet (NYSE: ZBH) with a Underweight rating and a price target of $104.00.

For an analyst ratings summary and ratings history on Zimmer Biomet click here. For more ratings news on Zimmer Biomet click here.

Shares of Zimmer Biomet closed at $106.91 yesterday.

You May Also Be Interested In

• Zimmer Biomet (ZBH) PT Raised to $100 at Canaccord
• Raymond James Starts SpyGlass Pharma (SGP) at Outperform
• BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform